Point Biopharma Global Inc - PNT STOCK NEWS

POINT Biopharma Global Inc. has operationalized its radiopharmaceutical manufacturing facility in Indianapolis to support the Phase 3 SPLASH trial for mCRPC. The facility began production of PNT2002 in January 2022, with expected top-line data from the trial due mid-2023. POINT will receive actinium-225 from the U.S. Department of Energy in 2022 to aid early-stage development, while also advancing regulatory discussions for PNT2003 targeting neuroendocrine tumors. The company aims to be a leader in the radiopharmaceutical space, leveraging its in-house manufacturing and secured isotope supplies.

POINT Biopharma Global Inc. announced the appointment of Matthew Vincent, Ph.D., J.D., as Senior Vice President of Business Development, effective January 4, 2022. Dr. Vincent has over 25 years of pharmaceutical business development experience, focusing on partnering and licensing, particularly in Asian markets. He aims to enhance POINT's strategic partnerships and drive the potential of its radiopharmaceuticals in cancer treatment. Previously, he held a senior role at Avacta Life Sciences and brings a strong background in oncology and immuno-oncology.

POINT Biopharma Global Inc. (NASDAQ: PNT) announced significant leadership changes effective December 1, 2021. Justyna Kelly has been promoted to Chief Operating Officer, bringing over 11 years of radiopharmaceutical experience. Dr. Robin Hallett has been elevated to Vice President of Discovery and Translational Sciences, focusing on the company’s pan-cancer programs. Dr. Sherin Al-Safadi will join as Vice President of Medical Affairs on December 13. Additionally, Jonathan Ross Goodman has been elected Lead Independent Director, while Michael Gottlieb has departed to pursue other opportunities.

POINT Biopharma has entered a technology licensing agreement with SCK CEN to enhance its production of no-carrier-added lutetium-177 (n.c.a. Lu-177). This collaboration aims to improve the company’s supply chain and reduce costs for n.c.a. Lu-177, which is essential for radiopharmaceuticals used in cancer treatment. The technology will enable POINT to efficiently produce a purer form of Lu-177, facilitating outpatient administration. Dr. Joe McCann announced the intent to ship their first clinical dose shortly, highlighting POINT's unique position in the radiopharmaceutical market.

POINT Biopharma Global Inc. (NASDAQ: PNT) will host a virtual educational event titled “The First Principles of Radiopharmaceuticals” on December 6, 2021, at 12:00 PM ET. The event is designed to provide insights into the unique qualities of radiopharmaceuticals in cancer treatment, including their manufacturing processes and short shelf lives. Attendees, including investors and industry stakeholders, will gain a deeper understanding of radiopharmaceuticals, highlighted by discussions led by the company's executive team. Registration is open online.

POINT Biopharma Global Inc. (NASDAQ: PNT) announced the initiation of the randomization phase in its Phase 3 SPLASH study of PNT2002 for metastatic castration-resistant prostate cancer (mCRPC). The company is on track to file an IND/CTA for PNT2004's lead, PNT6555, in early 2022. The new Indianapolis manufacturing facility is fully operational, with the first clinical product shipment expected by fiscal year-end 2021. Financially, the company reported a net loss of $17.1 million for Q3 2021, significantly higher than the $3.0 million loss in Q3 2020, with R&D expenses rising to $13.0 million.

POINT Biopharma Global Inc. (NASDAQ: PNT) has entered a long-term supply agreement with IONETIX Corporation for actinium-225 (Ac-225), aimed at bolstering POINT's drug development and clinical trials for Ac-225-based therapies. The agreement supports investigational studies for PNT2001, targeting non-metastatic castrate-sensitive prostate cancer, and PNT2004, a candidate for various cancers. POINT emphasizes utilizing the most effective radioisotope to advance their innovative radiopharmaceutical platform, enhancing their supply chain in collaboration with IONETIX.

POINT Biopharma Global Inc. (NASDAQ: PNT) announced a long-term agreement with Kinectrics Inc. for the supply of Ytterbium-176 (Yb-176), crucial for its Lutetium-177 (Lu-177) production. This partnership aims to secure a stable North American supply of n.c.a. Lu-177, which enhances patient access to radiopharmaceutical therapies. The agreement is expected to bolster POINT’s position in the radiopharmaceutical market and reduce the administrative burden on clinics, improving patient care.

ARTMS Inc. has submitted a Type 1 Master File to Health Canada for gallium-68 (Ga-68) production, aimed at addressing supply constraints of this vital medical isotope used in PET imaging. This strategic move includes a collaboration with POINT Biopharma and CanProbe to enhance the development of innovative radiopharmaceuticals in Canada. The Ga-68 regulatory filing is intended to improve supply chain efficiency and reduce costs while increasing availability through ARTMS' QUANTM Irradiation System, expected to significantly boost Ga-68 production capacity.